- ISIN
- US1569441009
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 25, 2024
Highlights
- Market Cap
- $5.60B
- Enterprise Value
- $5.57B
- EPS (TTM)
- -$1.61
- Total Revenue (TTM)
- $5.07M
- Gross Profit (TTM)
- -$2.54M
- EBITDA (TTM)
- -$191.51M
- Year Range
- $23.65 - $75.50
- Target Price
- $79.86
- ROA (TTM)
- -11.15%
- ROE (TTM)
- -11.59%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CGON Performance Chart
CG Oncology, Inc (CGON) is up 59.6% since the beginning of the year. At $66 per share, CGON is trading 12.3% below its 52-week high of $76.
Loading charts...
Returns By Period
CG Oncology, Inc (CGON) has returned 59.56% so far this year and 159.30% over the past 12 months.
CG Oncology, Inc
- 1D
- 8.46%
- 1M
- 3.11%
- YTD
- 59.56%
- 6M
- 65.29%
- 1Y
- 159.30%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
CGON Monthly Returns History
Based on dividend-adjusted daily data since Jan 25, 2024, CGON's average daily return is +0.22%, while the average monthly return is +3.67%. At this rate, an investment would double in approximately 1.6 years.
Historically, 57% of months were positive and 43% were negative. The best month was Sep 2025 with a return of +50.2%, while the worst month was May 2024 at -18.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, CGON closed higher 49% of trading days. The best single day was Jan 9, 2026 with a return of +29.3%, while the worst single day was May 6, 2025 at -23.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 25.36% | 12.97% | 15.10% | -1.39% | -6.67% | 6.36% | 59.56% | ||||||
| 2025 | 4.85% | -14.00% | -5.30% | 10.00% | -4.90% | 1.48% | 2.65% | 0.49% | 50.19% | 7.42% | 3.63% | -7.40% | 44.77% |
| 2024 | 28.48% | 19.99% | -1.81% | -8.45% | -18.94% | -3.10% | 5.64% | 10.58% | 2.30% | -5.83% | -2.20% | -17.47% | -1.10% |
Benchmark Metrics
CG Oncology, Inc has an annualized alpha of 31.94%, beta of 1.48, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since January 25, 2024.
- This stock captured 121.00% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -23.21%) - a profile typical of hedging or uncorrelated assets.
- R2 of 0.12 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 31.94%
- Beta
- 1.48
- R²
- 0.12
- Upside Capture
- 121.00%
- Downside Capture
- -23.21%
Return for Risk
Risk / Return Rank
CGON ranks 93 for risk / return — in the top 93% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for CG Oncology, Inc (CGON) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CGON | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.76 | ||
| Sortino ratioReturn per unit of downside risk | +0.90 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 1.37 | +0.05 |
| Calmar ratioReturn relative to maximum drawdown | 5.85 | 2.78 | +3.06 |
| Martin ratioReturn relative to average drawdown | 18.07 | 12.44 | +5.63 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the CG Oncology, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the CG Oncology, Inc was 67.47%, occurring on Apr 8, 2025. Recovery took 190 trading sessions.
The current CG Oncology, Inc drawdown is 10.47%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -67.47%Apr 2025 | 1y 1mo | 9mo 6d | 1y 10moFeb 2024 - Jan 2026 |
2026 bear market2026 | -27.41%Jun 2026 | 22d | — | 1mo 11dMay 2026 - now |
2026 correction2026 | -13.88%Feb 2026 | 14d | 15d | 29dJan 2026 - Feb 2026 |
2026 correction2026 | -11.82%Apr 2026 | 9d | 14d | 23dApr 2026 - May 2026 |
2026 pullback2026 | -6.99%Mar 2026 | 6d | 14d | 20dMar 2026 - Apr 2026 |
Drawdown Indicators
| CGON | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.47% | -56.78% | -10.69% |
Max Drawdown (1Y)Largest decline over 1 year | -27.41% | -9.10% | -18.31% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -10.47% | -1.80% | -8.67% |
Average DrawdownAverage peak-to-trough decline | -25.80% | -10.71% | -15.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.85% | 2.03% | +6.82% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of CG Oncology, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how CG Oncology, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CGON relative to other companies in the Biotechnology industry. Currently, CGON has a P/S ratio of 1,028.1. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CGON in comparison with other companies in the Biotechnology industry. Currently, CGON has a P/B value of 5.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CGON
Add CG Oncology, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CGON